|
|
 
|
|
Bryan
Byong Jin Kim, D.M.D.,
President and CEO
Dr. Kim has had extensive experience in
building successful organizations throughout his career. During
his tenure as Director and Senior Director of Corporate Development
at VGX Pharmaceuticals, Dr. Kim has played an important role in
the acquisition of VGX International, Inc. in 2005 as well as the
day-to-day management of this publicly-traded bio-pharmaceutical
company in Korea. VGX International was added to a KOSPI 200 index
in 2007. He also successfully launched 3 business units: new drug
development, CMO and cGMP consulting at VGX International.
Currently, he is a CEO of VGX International and a CEO of BRI, a
joint CMO company in Korea. Prior to joining VGX, Dr. Kim was a
successful private clinician and a Clinical Assistant Professor
at the University of Pennsylvania, School of Dental Medicine, where
he developed innovative clinical programs and directed important
research projects granted by NIDH in microbiology and immunology.
Dr. Kim holds a Bachelor of Arts degree in Economics and a Bachelor
of Science degree in Biological Science, both from University of
California at Irvine and a Doctor of Dental Medicine degree from
the University of Pennsylvania.
Jay J. Surh,
Chief Financial Officer, Vice President
Mr. Surh has over 30 years
of experiences in various industries ranging from textile trading
to IT related ventures. He started his career, right after his MBA
studies, as an Executive Trainee of IBM Korea. Since then, he began
accumulating knowledge and experiences in various industries including
textile trading, IT, computers, engineering, finance/accounting,
and construction. His career in these industries not only presented
him with various experiences but also exposed him to valuable international
business scenes. Later he became an entrepreneur himself, leading
an internet related joint venture in San Diego, California. Recently
he worked, as a Senior Advisor, for a venture capital investment
company specialized in incubating young and small companies. In
October, 2005, he joined VGX International, Inc. that then was in
the process of acquiring a publicly held corporation in Korea, as
Executive Director in charge of Finance/Accounting. This new position
enables him to exercise and capitalize knowledge and experience
he has been accumulating through 30 years of his careers for the
company, which he is now determined to extend over to VGXI, Inc.,
a new subsidiary of VGX International, as CFO.
Mr. Surh has a MBA in Finance and International Business from the
School of Business at the University of Michigan and a Bachelor
of Science in Mathematics from Eastern Michigan University.
Henry
Hebel, Chief Operating
Officer, Vice President
Mr.
Hebel joined VGX (Advisys) in 2001. He was previously employed by
Qiagen Inc., where he served as Key Account Manager for a strategic
joint venture known as the “pAlliance.” Mr. Hebel worked
on the team that launched this venture and was responsible for sales,
marketing, and project management activities. For six years prior
to his work at Qiagen, Mr. Hebel worked for GeneMedicine Inc., which
eventually merged to become Valentis, Inc. During this period, Mr.
Hebel served as Senior Manager of Bioprocessing. The Bioprocessing
team designed, built and operated a cGMP manufacturing facility that
was responsible for human clinical batches through Phase II trials,
as well as developed novel manufacturing techniques to allow for the
scale up of plasmid processes. Mr. Hebel has additional development
and manufacturing experience from Tanox Biosystems, Inc. In his position
at Tanox, Mr. Hebel worked on antibody product development.
Mr.
Hebel holds a Bachelor of Science degree in zoology from Texas A&M
University.
Jerry Brandewie, Director,
Manufacturing
Mr. Brandewie came to VGXI, Inc. with 26 years experience in product manufacturing. He joins VGXI from Vivante GMP Solutions (formerly Introgen Therapeutics) where he held the position of Vice President of Production. At Vivante he set up the systems and procedures for the production of live viral products for the treatment of cancer. He has extensive experience in start-up and scale-up of production facilities. Specifically, developing manufacturing procedures and strategies to increase production, improve productivity, product quality and efficiency.
Mr. Brandewie holds a Bachelor's degree in Chemistry from the University of Texas – Austin. He is also a member of the International Society for Pharmaceutical Engineering.
Dorothy Peterson,
Sr. Director of Quality
Ms. Peterson comes to VGX with over 20 years
experience in the medical device industry, complying with FDA regulations
in both start up and established organizations. Ms. Peterson recently
relocated to Houston, TX from San Diego, CA where she was VP of Operations
at Qualigen, Inc. which included the responsibility for quality and
regulatory. While at Qualigen, she successfully submitted several
510(k) applications and led the company through multiple regulatory
agency audits including ISO 13485 to gain the CE mark. Prior to Qualigen,
Ms. Peterson was at Hybritech, Inc. (a subsidiary of Beckman-Coulter)
for 14 years where she held multiple positions in both the quality
and manufacturing organizations.
Ms. Peterson received her Bachelor of Science in Biology from Sam
Houston State University in Huntsville, Texas. She is also a member
of the Regulatory Affairs Professional Society.
|
|
